A tumour’s upregulation of PD-L1/PD-L2, driven by HER2 signalling, cytokines, or hypoxia, suppresses these effector cells and limits ADCC, reducing therapeutic efficacy. This evidence concerns the gene ERBB2 and neoplasm.